Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples

References

• BALLS, M. and FENTEM J. H., 1997, Progress toward the validation of alternative tests. ATLA—Alternatives to Laboratory Animal, 25,33–43.
   Google Scholar
• BERTHOU, F., RATANASAVANH, D., RICHE, C., PICART, D., VOIRIN, T. and Gun,Louzo, A., 1989, Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver. Xenobiotica, 19,401–417.
   Google Scholar
• BOOBIS, A. R., BRODIE, M. J., KAHN, G. C., FLETCHER, D. R., SAUNDERS, J. H. AND DAVIES, D. S., 1981, Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. British Journal of Clinical Pharmacology, 9,11–19.
   Google Scholar
• BROLY, F., LIBERSA, C. and LHERMITTE, M., 1990, Mexiletine metabolism in vitro by human liver. Drug Metabolism and Disposition, 18,362–368.
   PubMedGoogle Scholar
• BROSEN, K., ZEUGIN, T. and MEYER, U. S., 1991, Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical Pharmacology and Therapeutics, 49,609–617.
   PubMed Web of Science ®Google Scholar
• COMBALBERT, J., FABRE, I., FABRE, G., DALET I., DERANCOURT, J., CANO, J. P. and MAUREL, P., 1989, Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P45011IA gene subfamily. Drug Metabolism and Disposition, 17,197–207.
   Google Scholar
• COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP), EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS: HUMAN MEDICINES EVALUATION UNIT, 1997, Note for guidance On the investigation of drug interactions (in press).
   Google Scholar
• EBNER, T., MEESE, C.O. and EICHELBAU M., 1995. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans. Molecular Pharmacology 48, 1078–1086.
   PubMed Web of Science ®Google Scholar
• ELLIS, S. W., CHING, M. S., WATSON, P. F., HENDERSON, C. J., SIMULA, A. P., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1992, Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochemical Pharmacology, 44,617–620.
   PubMed Web of Science ®Google Scholar
• EUGSTER, H. P. and SENGSTAG, C., 1993, Saccharomyces cerevisiae: an alternative source for human microsomal liver enzymes and its use in drug interaction studies. Toxicology, 82,61–73.
   PubMedGoogle Scholar
• FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERINGHAM, N. R., MCLAREN, A. W., MILES, J. S., SICETT, P. and WOLF, C. R. 1992, Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359–368.
   PubMed Web of Science ®Google Scholar
• GHOSAL, A., SATOH, H., THOMAS, P. E., BUSH, E. and MOORE, D., 1996, Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition, 24, 940–947.
   PubMed Web of Science ®Google Scholar
• GILLAM, E. M. and REILLY, P. E., 1988, Phenacetin 0-deethylation by human liver microsomes: kinetics and popranolol inhibition. Xenobiotica, 18, 95–104.
   PubMed Web of Science ®Google Scholar
• GORSKI, J. C., HALL, S. D., JONES, D. R., VANDENBRANDEN, M. and WRIGHTON, S. A., 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 47, 1643–1653.
   PubMed Web of Science ®Google Scholar
• GRANT, D M., CAMPBELL, M. E., TANG, B. K. and KALO W., 1987, Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies, Biochemical Pharmacology, 36, 1251–1260.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., BRIAN, W. R., IWASAKI, M., SARI, M. A., BAARNHIELM, C. and BERNTSSON, P., 1991, Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-45011IA4. Journal of Medicinal Chemistry, 34, 1838–1844.
   PubMed Web of Science ®Google Scholar
• HARRELL, A. W., WHEELER, S. M., PENNICK, M., CLARICE, S. E and CHEERY, R. J., 1993, Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metabolism and Disposition, 21, 18–23.
   PubMedGoogle Scholar
• HARRIS, J. W., RAHMAN, A., KIIVI, B. R., GUENGERICH, F. P. and COLLINS, J. M., 1994, Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Research, 54, 4026–4035.
   PubMed Web of Science ®Google Scholar
• IMAOKA, S., ENOMOTO, K., ODA, Y., ASADA, A., FUJIMORI, M., SHEVIADA, T., FUJITA, S., GUENGERICH F. P. and FUNAE, Y., 1990, Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. Journal of Pharmacology and Experimental Therapeutics, 255, 1385–1391.
   Google Scholar
• INABA, T., TAIT, A., NAKANo, M., MAHON, W. A. and KALO W., 1988, Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation. Drug Metabolism and Disposition, 16, 605–608.
   PubMed Web of Science ®Google Scholar
• KAMINSKY, L. S. and ZHANG, Z. Y., 1997, Human P450 metabolism of warfarin. Pharmacology and Therapeutics, 73, 67–74.
   PubMed Web of Science ®Google Scholar
• KATO, R. and YAMAZOE, Y., 1994, The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics, 4, 359–362.
   PubMedGoogle Scholar
• KRONBACH, T., 1991, Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450I1D6. Methods in Enzymology, 206, 509–517.
   PubMed Web of Science ®Google Scholar
• LING, K. H., LEEsoN, G. A., BURMASTER, S. D., HOOK, R. H., REITH, M. K. and CHENG, L. K., 1995, Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metabolism and Disposition, 23, 631–636.
   PubMed Web of Science ®Google Scholar
• LOWRY,O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurements with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• LUCAS, D., MENEZ, J. F. and BERTHOU, F., 1996, Chlorzoxazone : an in vitro and in vivo substrate probe for liver CYP2E1. Methods in Enzymology, 272, 115–123.
   PubMedGoogle Scholar
• MINERS, J.O., SMITH, K. J., ROBSON, R. A., McMANus, M. E., VERONESE, M. E. and BIRICETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Phar-macology, 37, 1137–1144.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., TSUTSUI, M., SATOH, T. and GONZALEZ, F. J., 1995, Chlorzoxazone is metabolized by human CYP 1A2 as well as by human CYP2E1. Pharmacogenetks, 5, 143–150.
   PubMedGoogle Scholar
• PEARCE, R. E., MCINTYRE, C. J., MADAN, A., SANZGIRI, U., DRAPER, A. J., BULLOCK, P. L., COOK, D. C., BURTON, L. A., LATHAM, J., NEvmrs, C. and PARKINSON, A., 1996, Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Archives of Biochemistry and Biophysics, 331, 145–169.
   PubMed Web of Science ®Google Scholar
• PECK, C. R., TEMPLE, R. and COLLINS, J. M., 1993, Understanding consequences of concurrent therapies. Journal of the American Medical Association, 269, 1550–1552.
   Web of Science ®Google Scholar
• RENAUD, J. P., CuLLIN, C., POMPON, D., BEAUNE, P. and MANSUY, D., 1990, Expression of human liver cytochrome P450 II1A4 in yeast. A functional model for the hepatic enzyme. European Journal of Biochemistry, 194, 889–896.
   PubMedGoogle Scholar
• RODRIGUES, A. D., 1994, Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochemical Pharmacology, 48, 2147–2156.
   PubMed Web of Science ®Google Scholar
• RUTTEN, A. A., FALKE, H. E., CATSBURG, J. F., TOPP, R., BLAAUBOER, B. J., VAN HOLSTEIJN, I., Doom, L. and VAN LEEUWEN, F. X., 1987, Interlaboratory comparison of total cytochrome P-450 and protein determinations in rat liver microsomes. Reinvestigation of assay conditions. Archives of Toxicology, 61, 27–33.
   PubMed Web of Science ®Google Scholar
• RUTTEN, A. A., FALKE, H. E., CATSBURG, J. F., WORTELBOER, H. M., BLAAUBOER, B. J., Doom, L., VAN LEELTWEN, F. X., THEELEN, R. and RIETJENS, I. M., 1992, Interlaboratory comparison of microsomal ethoxyresorufin and pentoxyresorufin 0-dealkylation determinations: standard-ization of assay conditions. Archives of Toxicology, 66, 237–244.
   PubMed Web of Science ®Google Scholar
• SESARDIC, D., Booms, A. R., EDWARDS, R. J. and DAVIES, D. S., 1988, A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the 0-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology, 26, 363–372.
   PubMed Web of Science ®Google Scholar
• SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990a, Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology, 29, 651–663.
   PubMed Web of Science ®Google Scholar
• SESARDIC, D., PASANEN M., PELKONEN, O. and BOOBIS, A. R., 1990b, Differential expression and regulation of members of the cytochrome P450IA gene subfamily in human tissues. Carcinogenesis, 11, 1183–1188.
   Google Scholar
• SHARER, J. E., SHIPLEY, L. A., VANDENBRANDEN, M. R., BINICLEY, S. N. and WRIGHTON, S. A., 1995, Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231–1241.
   PubMed Web of Science ®Google Scholar
• SHIMADA, S., MIMURA, M., INOUE, K., NAKAMARA, S., ODA, H., OHMORI, S. and YAMAZAKI, H., 1997, Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys and humans. Archives of Toxicology, 71, 401–408.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL W., BIRKETT, D. J., VERONESE, M. E., McMANus, M. E., TUKEY, R. H., QUATTROCHI L. C., GELBOIN, H. V. and MINERS, J.O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401–407.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL W., MOHAMED, Z., BIRKETT, D. J., McMANus, M. E., VERONESE, M. E., TUKEY, R. H., QUATTROCHI, L. C., GONZALEZ, F. J. and MINERS, J.O., 1992, Caffeine as a probe for human cyto chrom es P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 2, 173–183.
   PubMedGoogle Scholar
• TEMPLE, R. J., 1996, The clinical pharmacologist in drug regulation: the US perspective. British Journal of Clinical Pharmacology, 42, 73–79.
   PubMedGoogle Scholar
• TRANSON, C., LECOEUR, S., LEEMANN, T., BEAUNE, P. and DAYER, P., 1996, Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. European Journal of Clinical Pharmacology, 51, 79–85.
   PubMed Web of Science ®Google Scholar
• US FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH, 1997, Guidance for industry. Drug metabolism/drug interaction studies in the drug development process: studies in vitro.
   Google Scholar
• VERONESE M. E., DOECKE, C. J., MACKENZIE, P.1., McMANus, M. E., MINERS, J.O., Rs, D. L., GASSER, R., MEYER, U. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal, 289, 533–538.
   Google Scholar
• WATKINs, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ -PICON, G., PARKER, G. A. and GUZELIAN, P. S., 1985, Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences, USA, 82, 6310–6314.
   Google Scholar
• WRINGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTIE, A. E. and CASHMAN, J. R., 1993, In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metabolism Reviews, 25, 453–484.
   PubMedGoogle Scholar
• YAMAZAKI, H., INouE, K., TURVY, C. G., GUENGERICH, F. P. and SHIMADA, T., 1997, Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metabolism and Disposition, 25, 168–174.
   PubMed Web of Science ®Google Scholar